On May 15, 2024 Novartis reported the company will present data from more than 60 abstracts, including investigator-initiated trials at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and the European Hematology Association (EHA) (Free EHA Whitepaper) 2024 Hybrid Congress (Press release, Novartis, MAY 15, 2024, View Source [SID1234643329]). The primary results from ASC4FIRST, a pivotal Phase III study of Scemblix (asciminib) versus standard of care tyrosine kinase inhibitors (imatinib, nilotinib, dasatinib, and bosutinib) in newly diagnosed patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) will be shared at the ASCO (Free ASCO Whitepaper) official Press Program and at the EHA (Free EHA Whitepaper) Plenary Session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Despite progress, people with CML continue to struggle to find treatment that is both efficacious and tolerable for them at diagnosis and beyond. We look forward to sharing the primary analysis from the pivotal Phase III ASC4FIRST trial, which builds on our over 20-year legacy to transform care for people diagnosed with CML," said Jeff Legos, Executive Vice President, Global Head of Oncology, Novartis. "With these promising data, a new analysis of the NATALEE trial in patients with node-negative early breast cancer and additional updates from our RLT portfolio, we further our efforts to reimagine medicine for those with cancer in partnership with the scientific community."

Key highlights of data accepted by ASCO (Free ASCO Whitepaper) include:

Medicine     Abstract Title     Abstract Number/ Presentation Details     
Scemblix ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results

Abstract #LBA6500
Oral presentation
Friday, May 31
2:45 – 5:45pm CDT

Kisqali (ribociclib)

Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial

Abstract #512
Rapid oral presentation
Friday, May 31
2:45 – 4:15pm CDT
Kisqali

On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3)

Abstract #1012
Clinical Science Symposium
Sunday, June 2
4:30 – 6:00pm CDT

Kisqali

Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis

Abstract #541
Poster presentation
Sunday, June 2
9:00am – 12:00pm CDT
Kisqali     Real-world (RW) risk recurrence among patients (pts) diagnosed with stage II-III HR+/HER2- early breast cancer (EBC) treated with endocrine therapy (ET) in the US
  Abstract #e12533
Online publication

Pluvicto (INN: lutetium (177Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan)

Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore)

Abstract #5003
Oral presentation
Saturday, June 1
3:00 – 6:00pm CDT

Pluvicto Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore

Abstract #5008
Oral presentation
Saturday, June 1
3:00 – 6:00pm CDT

Pluvicto Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer

Abstract #e17043
Online publication

Pluvicto Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists

Abstract #e17048
Online publication
Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate)

Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study

Abstract #4131
Poster presentation
Saturday, June 1
1:30 – 4:30pm CDT

At the ASCO (Free ASCO Whitepaper) Annual Meeting, Novartis will also address health equity at the company’s booth on the meeting floor, with the More Than Just Words virtual reality experience. Meeting attendees will have the opportunity to immerse themselves in scenarios inspired by real-life microaggressions Black patients face due to bias in care, and explore resources co-created with leading multidisciplinary experts to help foster productive, nonbiased conversations about breast cancer risk, diagnosis, and care.

Key highlights of data accepted by EHA (Free EHA Whitepaper) include:  

Medicine   Abstract Title Abstract Number/ Presentation Details     
Scemblix Asciminib (ASC) provides superior efficacy and excellent safety and tolerability vs tyrosine kinase inhibitors (TKI) in newly diagnosed chronic myeloid leukemia (CML) in the pivotal ASC4FIRST study

Abstract #S103
Plenary oral presentation
Saturday, June 15
2:45 – 4:15pm CEST

Scemblix Asciminib (ASC) is well tolerated in pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP): interim pharmacokinetics and safety results from ASC4KIDS 

Abstract #P1865
e-Poster presentation

Fabhalta (iptacopan)

Effects of oral iptacopan monotherapy, including increased paroxysmal nocturnal hemoglobinuria red blood cell clone size, are sustained in anti-c5-treated patients with anemia: final APPLY-PNH data Abstract #P829
Poster presentation
Friday, June 14
9:00am CEST
Fabhalta

Effects of oral iptacopan monotherapy, including increased paroxysmal nocturnal hemoglobinuria red blood cell clone size, are maintained in complement inhibitor-naïve patients: final APPOINT-PNH data

Abstract #P822
Poster presentation
Friday, June 14
9:00am CEST

Fabhalta

Patient experience of iptacopan in three clinical trials for paroxysmal nocturnal hemoglobinuria

Abstract #P1918
e-Poster presentation
Product Information 
For full prescribing information, including approved indications and important safety information about marketed products, please visit View Source